We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pioglitazone in acromegaly - an open-label, prospective study.
- Authors
Kim, David D. W.; Goh, Jovina; Panossian, Zaven; Gamble, Greg; Holdaway, Ian; Grey, Andrew
- Abstract
Objective Preclinical studies demonstrate that thiazolidinediones ( TZDs) decrease growth hormone ( GH) and insulin-like growth factor-1 ( IGF-1) levels, suggesting that they might be effective treatments for acromegaly. This study investigated the effect of pioglitazone on biochemical indices of disease activity in acromegaly. Design and participants This was a 4-month open-label prospective study in 16 patients with active acromegaly who were attending public hospital endocrinology clinics. Methods The intervention was pioglitazone 45 mg/day. The primary outcome was change in serum IGF-1; the secondary outcome was change in area under the curve of glucose-suppressed GH. Results Serum IGF-1 did not change during treatment with pioglitazone ( P = 0·95). After 4 months, the mean (95% CI) change from baseline was −1 μg/l (−51, 49). GH levels following oral glucose loading were unchanged during pioglitazone therapy. After 4 months, the mean (95% CI) change from baseline in area under curve for glucose-suppressed GH was 31 μg/l (−75, 138, P = 0·54). Conclusions Short-term treatment with conventional doses of pioglitazone did not improve biochemical measures of disease activity in acromegaly.
- Subjects
ACROMEGALY treatment; PIOGLITAZONE; THIAZOLIDINEDIONES; SOMATOTROPIN; SOMATOMEDIN C; GLUCOSE; LONGITUDINAL method
- Publication
Clinical Endocrinology, 2012, Vol 77, Issue 4, p575
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1111/j.1365-2265.2012.04411.x